Dewpoint's New Drug Takes Aim at 'Undruggable' Cancer Driver MYC

By Alexander Harris

BOSTON, MA – April 21, 2026 – Decades of cancer research have been haunted by a formidable foe: a protein named MYC. Implicated in up to 70% of human cancers, MYC is a master regulator that fuels uncontrolled cell growth, but its very nature has made it famously 'undruggable.' Today, at the American Association for Cancer Research (AACR) Annual Meeting, Boston-based Dewpoint Therapeutics unveiled data suggesting a potential new way to conquer this elusive target, not by attacking MYC directly, but by dismantling the cellular machinery it needs to function.

The company presented compelling preclinical data for its orally bioavailable MYC development candidate. In animal models of solid tumors, the compound successfully drove tumor regression and stasis, demonstrating a potent anti-cancer effect coupled with a favorable safety profile. This announcement marks a significant step forward for a novel field of drug discovery and offers a glimmer of hope against one of oncology's most challenging targets.

The 'Holy Grail' of Oncology

For decades, MYC has been considered a 'holy grail' for cancer drug developers. Its central role in driving the proliferation of cancer cells is well-documented, yet it has consistently evaded therapeutic intervention. The reasons for this are rooted in its fundamental biology.

Unlike many other protein targets that have well-defined, stable pockets for drugs to bind to, MYC is an intrinsically disordered protein. It lacks a fixed three-dimensional structure, resembling a constantly shifting strand rather than a rigid lock for a drug 'key.' This structural chaos makes designing a small molecule to inhibit it directly an immense challenge.

Furthermore, MYC carries out its oncogenic mission inside the cell nucleus, a difficult-to-reach location for many types of drugs. Complicating matters further, MYC is not just a cancer protein; it is also essential for the normal function and proliferation of healthy cells. A drug that indiscriminately wipes out all MYC activity could cause severe, unacceptable toxicity throughout the body, making the search for a therapeutic window incredibly narrow.

A New Paradigm: Disrupting the Condensate

Instead of confronting the MYC protein head-on, Dewpoint Therapeutics is pioneering a radically different strategy: targeting biomolecular condensates. These structures are dynamic, membraneless organelles that form within cells through a process called phase separation, much like oil droplets forming in water. Condensates act as cellular hubs, concentrating specific proteins and nucleic acids to organize and amplify critical processes like gene transcription.

Dewpoint’s research suggests that MYC requires the formation of these specialized transcriptional condensates to effectively execute its cancer-driving gene expression program. By developing a drug that disrupts the formation or stability of these specific MYC-associated condensates, the company aims to selectively shut down MYC's oncogenic activity without directly binding the protein itself. This approach effectively disarms the protein by taking away the environment it needs to function.

“MYC has remained out of reach for decades,” said Ann Boija, SVP and Head of Research at Dewpoint, in a statement accompanying the announcement. “These data establish a new path to targeting key oncogenic transcription factors such as MYC, overcoming longstanding limitations in the field. We see strong potential for this approach to translate into meaningful therapeutic impact for patients.”

The data presented at AACR showed that Dewpoint's oral compound successfully reduced MYC condensates, modulated MYC-dependent gene expression, and resulted in the selective killing of cancer cells with high levels of MYC, all while being well-tolerated in preclinical models.

“We believe condensate biology defines a new frontier for drug discovery,” added Isaac Klein, Chief Scientific Officer of Dewpoint Therapeutics. “By targeting the organizational principles of the cell, we can systematically access disease-driving mechanisms that have historically been beyond reach.”

A Crowded Field with a Differentiated Approach

The pursuit of a MYC inhibitor is a highly competitive field. Several companies are making progress with different strategies. Peptomyc's OMO-103, a mini-protein that directly inhibits MYC, has shown promise in early clinical trials, proving that targeting MYC is no longer a theoretical exercise. Other approaches focus on indirect inhibition by targeting the pathways that regulate MYC's transcription or stability, using molecules like BET inhibitors or PROTACs designed to degrade the protein.

Dewpoint’s condensate modulation strategy stands apart from these efforts. It represents a new therapeutic modality that could circumvent the challenges of direct binding and potentially offer a more nuanced way to control the protein's function. The success of this approach not only validates Dewpoint's platform but also strengthens the case for condensate biology as a major new frontier in medicine, with potential applications in neurodegenerative and cardiometabolic diseases as well.

While the journey from promising preclinical data to an approved human therapy is long and uncertain, this milestone is a significant validation for the company's science. Dewpoint already has a β-catenin modulator in clinical trials for solid tumors, demonstrating its ability to advance these novel c-mods into human testing. With strong collaborations with industry giants like Bayer and Novo Nordisk, the company is well-positioned to continue exploring this new biological frontier. The data presented today suggests that after decades of frustration, the walls around the fortress of MYC may finally be starting to crumble.